
OnCusp Therapeutics Receives FDA Fast Track Designation for CUSP06 for the Treatment of Platinum-Resistant Ovarian Cancer
Published on February 12, 2025
oncology assets for patients. OnCusp raised an oversubscribed $100 million Series A financing round in January 2024 , co-led by Novo
Other news
